Additionally, per the ASCO, TMB testing may be pursued in R/M HNSCC cancer patients without a CPS or in patients with rare tumors, and a TMB score of >10 is interpreted as being consistent with a clinical benefit of PD-1/PD-L1 system inhibition [2]. Here, PDCD1 is linked to head and neck squamous cell carcinoma.